

CHARTER FOR THE QUALITY OF MEDICINES, VACCINES, DIAGNOSTIC PRODUCTS AND SMALL MEDICAL MATERIALS

Introduction

Our organizations are part of a platform, Be-cause Health (www.be-causehealth.be), that includes all Belgian actors active in international health care and the promotion of access to high level health care. Through consultation, coordination and the organization of common activities, this platform tries to bridge the academic world and the field workers. *As to medicines, Be-cause Health takes as reference the World Health Organization (WHO) and other agencies with recognized expertise and mandate in this field.*

The quality of medicines administered to patients currently represents one of the major concerns of many national and international organizations active in international health care.

As medical organizations, we are expected to deliver medicines, vaccines, medical materials and diagnostic equipments to the patients in our programmes. To make sure that curative and preventive health care are of appropriate quality, we have to assure the quality of the medicines, vaccines, small medical materials and diagnostic equipments that are used in our health care programmes.

That is why our organizations commit themselves to contribute to install or strengthen a quality assurance (QA) system for medicines, vaccines, small medical materials and diagnostic materials. To achieve this aim, we will adopt essential quality criteria for the purchase of these products, as defined in this Quality Assurance Charter.

This decision is expected to contribute to an improvement of the regulation of the international pharmaceutical market, in a cultural and ethical framework where quality and shared responsibility are of high importance for all the concerned actors.

The organizations who sign up to this charter,

As every patient, no matter where he or she lives, has the right to be treated with medicines of verified quality, and vaccines of verified quality with small medical materials and diagnostic materials of verified quality;

As the products at the disposal of our teams must have the same quality and safety standards as in our own countries;

As the current situation is worrying;

Adopt the following Quality Assurance system for medicines, vaccines, small medical materials and diagnostic devices:

To guarantee the quality of the products at the disposal of the projects of our organizations in resource-poor contexts, the medicines, vaccines, medical materials and the *in vitro* diagnostic medical devices *which we consider essential*, must comply with:

- the norms and standards defined by the WHO (see technical reports¹)
- the acknowledged International Pharmacopeias²
- the norms and the standards defined by the International Society for Blood Transfusion (ISBT)(see technical reports³)
- or the norms and standards defined by the European Union (EU), **only** for the products mentioned in the Annex II A and B of the Directive 98/79/EC of the EU (see technical reports⁴).
- Ou aux normes et standards définis par l'Union Européenne (U.E.) **uniquement** pour les produits repris dans l'Annexe II A et B de la Directive 98/79/EC de l'U.E. (cf. rapports techniques⁵).

We consider the following products *de facto* to be qualified for our organization:

- all pharmaceutical products pre-qualified by the WHO Pre-qualification Project;
- all pharmaceutical products registered in a high-regulated country (list of ICH: European Union, United States and Japan) and which are in our list of essential medicines;
- all vaccines pre-qualified by the WHO;
- all vaccines registered in a high-regulated country, and which are in our list with essential products;
- all medical materials and *in vitro* diagnostic medical devices, qualified or pre-qualified by the WHO and/or by the International Society for Blood Transfusion (ISBT);
- all *in vitro* diagnostic medical devices authorized in Europe and included in the annex II A and B of the directive 98/79/EC from the European Union and which are in our list of essential products;
- all medical materials and diagnostic medical devices authorized in a high-regulated country (United States) and which are in our list of essential products.

We reserve the right to verify that products that do not meet the above criteria comply with the appropriate standards (see annexes 1 and 2). These evaluations

¹ WHO Technical Report Series 937/ WHO Expert Committee on specifications for pharmaceutical preparation, 40th report and any updates ; http://www.who.int/diagnostics_laboratory/evaluations/en/ ; http://www.who.int/std_diagnostics/publications/manuals/default.htm ; <http://www.wpro.who.int/sites/rdt> (date accès : 24/10/2007).

² WHO International Pharmacopoeia, US Pharmacopoeia, British Pharmacopoeia, European Pharmacopoeia.

³ <http://www.icbs-web.org/page11.html> (date accès : 24/10/2007).

⁴ <http://europa.eu.int/eur-lex/lex/LexUriServ/site/en/consleg/1998/L/01998L0079-20031120-en.pdf> (date accès : 24/10/2007)

⁵ <http://europa.eu.int/eur-lex/lex/LexUriServ/site/en/consleg/1998/L/01998L0079-20031120-en.pdf> (date accès : 24/10/2007)

may be delegated to institutions or organizations which we consider to have the appropriate tools to perform this control.

The members of Be-cause Health who sign this charter commit themselves to work with professional auditors⁶ who will be responsible for the supervision and of the approved manufacturing sites. The audits will be conducted according to the standards of Good Manufacturing Practices (GMP of the WHO).

After purchase and delivery, samples of the purchased products can at any time be sent to an accredited laboratory for analysis.

Declaration of honor

The distributor or manufacturer gives his word of honor:

- that he agrees to collaborate, if necessary, with the auditors appointed by our organizations
- that the information provided to the members of Because Health is accurate and correct
- that any changes in the manufacturing process or any changes of the source of a product will be promptly communicated

Every mistake or omission, whether intentional or not, can lead to an immediate disqualification of the product(s) and/or the manufacturer.

It can also lead to the annulment of all commercial contract concluded on this basis.

⁶ WHO Technical Report Series 937/ WHO Expert Committee on specifications for pharmaceutical preparation, 40th report and any updates